CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--NuPathe Inc., a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system announced today that the Company will present the results of a new study and a subgroup analysis from its Phase III pivotal trial for Zelrix™, a single-use transdermal sumatriptan patch being developed for the treatment of migraine, at the 52nd Annual Scientific Meeting of the American Headache Society.
